Tesamorelin (Egrifta)

Tesamorelin’s evaluated population has HIV-associated lipodystrophy. The product information states it is not indicated for weight-loss management. A change in abdominal fat in that population does not establish a general benefit for someone seeking a leaner appearance. ^{1, 2}

IGF-1 and glucose effects are relevant to monitoring. Active malignancy, pregnancy and disruption of the hypothalamic-pituitary axis are important exclusions. Fluid retention, joint symptoms, injection-site reactions and allergy can occur. The actual label should guide an individual assessment. ²

Egrifta SV and WR are not automatically substitutable. A combination with ipamorelin or MOTS-c is a different preparation and cannot inherit Egrifta’s approval or study outcomes. Ask whether the evidence addresses the actual formulation and patient population. ²

The labeled goal is reduction of excess abdominal fat in adults with HIV and lipodystrophy, not general weight loss. Weight, waist size or a body-composition scan can change for many reasons and should not be presented as proof that the labeled condition is improving. The label states that long-term cardiovascular safety has not been established and treatment does not replace HIV care, nutrition or activity planning. A clinician should define the clinical reason and reassessment point before treatment starts. ^{1, 2}

Tesamorelin can increase IGF-1 and can cause glucose intolerance or diabetes. Follow-up may include glucose and IGF-1 measurements and review of swelling, joint symptoms, carpal-tunnel symptoms and injection reactions. Active malignancy is a contraindication, and prior cancer requires careful consideration. Pregnancy is also contraindicated because visceral-fat changes are not beneficial during pregnancy and fetal harm may occur. These risks do not disappear when tesamorelin is placed into a peptide mixture. ^{1, 2}

Egrifta SV and Egrifta WR are distinct products with their own preparation, storage and administration instructions. Do not substitute versions or copy reconstitution steps between them. A compounded tesamorelin vial or combination with ipamorelin or MOTS-c is another intervention and does not inherit Egrifta approval. Rotate injection sites and report severe allergy symptoms, persistent swelling or significant glucose symptoms. Pharmacy instructions must identify the exact diluent, final concentration and device without relying on online peptide protocols. ^{1, 2}

Tesamorelin is contraindicated in pregnancy. Visceral fat normally increases as part of pregnancy, so reducing it offers no known benefit and may cause fetal harm. People who can become pregnant need a contraception and testing plan appropriate to their situation. If pregnancy occurs, contact the prescriber promptly and do not substitute another growth-hormone-related peptide or weight-management product on your own. ^{1, 2}